Should I Buy PRLD? PRLD 2026 Analysis

Should You Buy Prelude Therapeutics Inc (PRLD) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

1.870

1 Day change

-5.08%

52 Week Range

4.220

Analysis Updated At

2026/01/26

Prelude Therapeutics Inc (PRLD) is not a strong buy at the moment for a beginner investor with a long-term strategy. While there are positive insider buying trends and revenue growth, the lack of significant trading signals, weak technical indicators, and declining financial metrics such as net income and EPS make it a less compelling investment opportunity right now.

Technical Analysis

The MACD histogram is negative (-0.087) and contracting, RSI is neutral at 43.302, and moving averages are converging, indicating no clear trend. Key support is at 1.831, and resistance is at 2.637. Overall, the technical indicators suggest a neutral to slightly bearish outlook.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Options data shows a relatively low put-call ratio, indicating a slight bullish sentiment, but the implied volatility (224.74%) and low IV percentile (6.8) suggest limited near-term price movement.

Technical Summary

Sell

Buy

Positive Catalysts

Insider buying has increased significantly (188.46% over the last month). Revenue growth is strong, up 116.67% YoY in Q3 2025.

Neutral/Negative Catalysts

Net income and EPS have declined significantly YoY (-38.88% and -39.53%, respectively). The stock lacks recent news or event-driven catalysts. No recent congress trading data or influential figure activity.

Financial Performance

In Q3 2025, revenue increased to $6.5M (up 116.67% YoY), but net income dropped to -$19.73M (-38.88% YoY), and EPS fell to -0.26 (-39.53% YoY). Gross margin remained stable at 100%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target changes available.

Analyst Rating

Wall Street analysts forecast PRLD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRLD is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold

Sell

Current: 1.970

Low

Averages

High

Current: 1.970

Low

Averages

High

Citizens JMP

Outperform -> NULL

downgrade

$4 -> $3

AI Analysis

2025-08-18

Reason

Citizens JMP

Price Target

$4 -> $3

AI Analysis

2025-08-18

downgrade

Outperform -> NULL

Reason

Citizens JMP lowered the firm's price target on Prelude Therapeutics to $3 from $4 and keeps an Outperform rating on the shares. With initial PRT3789 monotherapy data validating the SMARCA2 target, the firm says PRT7732 has a path forward as a combination agent, the analyst tells investors in a research note.

HC Wainwright & Co.

Robert Burns

Strong Buy

Reiterates

2025-04-08

Reason

HC Wainwright & Co.

Robert Burns

Price Target

2025-04-08

Reiterates

Strong Buy

Reason

PRLD Should I Buy

PRLD Should I Buy

Should You Buy Prelude Therapeutics Inc (PRLD) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch